title: Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.
abstract: BACKGROUND
  Although the use of tumour necrosis factor (TNF) antagonists is increasingly codified, several unresolved issues remain.
  
  
  OBJECTIVE
  To conduct a French national survey on TNF antagonists use in inflammatory bowel disease (IBD).
  
  
  METHODS
  A postal questionnaire was sent to all French gastroenterologists among whom 450 prescribe TNF antagonists for IBD. Only anti-TNF prescribers were invited to respond.
  
  
  RESULTS
  A total of 333 questionnaires could be analysed, which represented a rate of survey completeness of 74%. Scheduled maintenance infliximab treatment was prescribed by 92% of gastroenterologists. In Crohn's disease in remission after 1 year of TNF antagonists, 77.4% of physicians continued treatment. In luminal Crohn's disease, 97% of hospital practitioners introduced infliximab as first-line anti-TNF therapy vs. 78% of physicians with nonhospital activity (P = 0.002); only 22.5% of gastroenterologists opted for adalimumab as first-line therapy. In Crohn's disease in remission after 6 months of azathioprine in combination with infliximab, 63.8% of practitioners discontinued azathioprine. In case of pregnancy during anti-TNF treatment, 35.1% of physicians discontinued therapy at the time of conception and did not administer anti-TNF therapy during pregnancy.
  
  
  CONCLUSIONS
  The attitudes of French gastroenterologists generally reflect the recommendations regarding the use of anti-TNF and concomitant immunosuppressive therapy in IBD.
authors.affiliation: Inserm, U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France.
authors.forename: A
authors.initials: A
authors.lastname: Oussalah
authors.forename: X
authors.initials: X
authors.lastname: Roblin
authors.forename: D
authors.initials: D
authors.lastname: Laharie
authors.forename: J
authors.initials: J
authors.lastname: Filippi
authors.forename: M
authors.initials: M
authors.lastname: Flamant
authors.forename: P
authors.initials: P
authors.lastname: Faure
authors.forename: J-M
authors.initials: JM
authors.lastname: Phelip
authors.forename: M-A
authors.initials: MA
authors.lastname: Bigard
authors.forename: L
authors.initials: L
authors.lastname: Peyrin-Biroulet
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001291:Attitude of Health Personnel; D004812:Epidemiologic Methods; D005602:France / Q000453:epidemiology; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D010818:Practice Patterns, Physicians'; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab